Second interim analysis data from phase IIa study of vilobelimab in pyoderma gangrenosum Aug. 11, 2021
Phase IIb/III ALLEGRO trial of ritlecitinib in alopecia areata meets primary efficacy endpoint Aug. 4, 2021
RSS